173 related articles for article (PubMed ID: 11295636)
21. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
[TBL] [Abstract][Full Text] [Related]
24. Is There a Future for Chemoprevention of Prostate Cancer?
Bosland MC
Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
Alberts SR; Blute ML
Urology; 2001 Apr; 57(4 Suppl 1):188-90. PubMed ID: 11295624
[TBL] [Abstract][Full Text] [Related]
26. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia.
Mohanty NK; Saxena S; Singh UP; Goyal NK; Arora RP
Urol Oncol; 2005; 23(6):383-5. PubMed ID: 16301113
[TBL] [Abstract][Full Text] [Related]
27. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
28. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
29. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
30. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
[TBL] [Abstract][Full Text] [Related]
32. Quality of Life endpoints in prostate chemoprevention trials.
Sloan JA; Varricchio C
Urology; 2001 Apr; 57(4 Suppl 1):235-40. PubMed ID: 11295635
[TBL] [Abstract][Full Text] [Related]
33. Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?
Hailemariam S; Vosbeck J; Cathomas G; Zlobec I; Mattarelli G; Eichenberger T; Zellweger T; Bachmann A; Gasser TC; Bubendorf L
Hum Pathol; 2011 May; 42(5):702-9. PubMed ID: 21237492
[TBL] [Abstract][Full Text] [Related]
34. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
35. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
Marshall JR
IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
[TBL] [Abstract][Full Text] [Related]
36. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
37. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
38. Models for prostate cancer chemoprevention.
Bubley G
Clin Prostate Cancer; 2003 Jun; 2(1):32-3. PubMed ID: 15046681
[No Abstract] [Full Text] [Related]
39. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?
Goeman L; Joniau S; Ponette D; Van der Aa F; Roskams T; Oyen R; Van Poppel H
Prostate Cancer Prostatic Dis; 2003; 6(4):305-10. PubMed ID: 14663472
[TBL] [Abstract][Full Text] [Related]
40. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
Cote RJ; Skinner EC; Salem CE; Mertes SJ; Stanczyk FZ; Henderson BE; Pike MC; Ross RK
Br J Cancer; 1998 Aug; 78(3):413-8. PubMed ID: 9703292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
